JulieReneeBrahmerMD

Thoracic Cancer

Professor of Oncology, Johns Hopkins University School of Medicine; Interim director, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus), Co-Director, Upper Aerodigestive Program

Join to view full profile

Dr. Brahmer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brahmer's full profile

Already have an account?

Office
600 N Wolfe St
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-614-9334

Summary

Dr. Julie Brahmer is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. She received her medical degree from University of Nebraska College of Medicine and has been in practice 24 years. She specializes in thoracic oncology and is experienced in gastrointestinal oncology, and general medical oncology.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Utah HealthResidency, Internal Medicine, 1993 - 1997
University of Nebraska College of MedicineClass of 1993

Certifications & Licensure

FL State Medical License 2021 - Present
MD State Medical License 1997 - 2026
VA State Medical License 2023 - 2026
DC State Medical License 2022 - 2024
PA State Medical License 2024 - 2024
UT State Medical License 1994 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Fellow (FASCO) American Society of Clinical Oncologists, 2011

Clinical Trials

Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
Completed
Not Applicable
Broccoli Sprout Extract in Preventing Lung Cancer in Smokers Start of enrollment: 2005 Jan 01
Completed
Not Applicable
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Start of enrollment: 2010 Apr 12
Completed
Phase 3
Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
Completed
Phase 1
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma Start of enrollment: 2011 Jun 01
Completed
Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer Start of enrollment: 2013 Mar 11
Completed
Not Applicable
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2013 May 01
Terminated
Phase 2
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC Start of enrollment: 2014 Sep 01
Active, not recruiting
Phase 2
Genetic Predictors of Benefit to Pembrolizumab Start of enrollment: 2016 May 31
Terminated
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Pan Tumor Rollover Study Start of enrollment: 2019 Aug 09
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

51 citations
Persistent mutation burden drives sustained anti-tumor immune responses.
Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst
Nature Medicine. 2023-02-01
21 citations
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Valsamo Anagnostou, Cheryl Ho, Garth Nicholas, Rosalyn Anne Juergens, Adrian Sacher
Nature Medicine. 2023-10-01
125 citations
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Valsamo Anagnostou, Noushin Niknafs, Kristen A. Marrone, Daniel C. Bruhm, James R. White
Nature Cancer. 2020-01-13

Journal Articles

Immune-Related (IR)-Pneumonitis During the COVID-19 Pandemic: Multidisciplinary Recommendations for Diagnosis and Management
Joshua E Reuss, Karthik Suresh, David Feller-Kopman, Clare Rock, Julie R Brahmer, Journal For Immunotherapy of Cancer

Lectures

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.
2019 ASCO Annual Meeting - 6/1/2019
General Management of Immune-Related Toxicities Incorporating Guidelines Into Practice
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Emerging Strategies in Treatment of Non−Small-Cell Lung Cancer and Head & Neck Cancer 2012
CancerNet, LLC, Atlanta, Georgia - 6/16/2012

Authored Content

Evaluation of Health-Related Quality of Life and Symptoms in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or Docetaxel in CheckMate 057September 2018

Press Mentions

Initiative for Managing Adverse Events of Immunotherapy Leads to Clinical Practice Changes at MD AndersonApril 4th, 2023
Cancer Research Institute Virtual Immunotherapy Patient Summit Is Now Available Free, on-DemandDecember 8th, 2022
Long-Term Clinical Benefit with Nivolumab plus Ipilimumab Extends Beyond Treatment Discontinuation in Patients with Metastatic NSCLC, Regardless of PD-L1 ExpressionOctober 18th, 2022
Join now to see all